MRK · Merck
283 filings
MRK 8-K Current Reports
Merck - 283 current reports
MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 88 current reports (8-K) between 2016 and 2026.
- 8-K · Feb 3, 2016
- 10-K · Feb 26, 2016
- 8-K · May 5, 2016
- 10-Q · May 9, 2016
- 8-K · May 27, 2016
- 8-K · Jul 29, 2016
- 10-Q · Aug 8, 2016
- 8-K · Oct 25, 2016
- 8-K · Nov 2, 2016
- 10-Q · Nov 7, 2016
- 8-K · Feb 2, 2017
- 8-K · Feb 23, 2017
- 10-K · Feb 28, 2017
- 8-K · May 2, 2017
- 10-Q · May 9, 2017
- 8-K · May 25, 2017
- 8-K · Jul 28, 2017
- 10-Q · Aug 8, 2017
- 8-K · Oct 27, 2017
- 8-K · Nov 6, 2017
- 10-Q · Nov 7, 2017
- 8-K · Jan 26, 2018
- 8-K · Feb 2, 2018
- 8-K · Feb 26, 2018
- 10-K · Feb 27, 2018
- 8-K · May 1, 2018
- 10-Q · May 8, 2018
- 8-K · May 24, 2018
- 8-K · Jul 27, 2018
- 10-Q · Aug 7, 2018
- 8-K · Sep 27, 2018
- 8-K · Oct 4, 2018
- 8-K · Oct 25, 2018
- 10-Q · Nov 6, 2018
- 8-K · Dec 10, 2018
- 8-K · Jan 30, 2019
- 8-K/A · Feb 1, 2019
- 8-K · Feb 1, 2019
- 10-K · Feb 27, 2019
- 8-K · Mar 7, 2019
- 8-K · Apr 30, 2019
- 10-Q · May 8, 2019
- 8-K · May 31, 2019
- 8-K · Jul 30, 2019
- 10-Q · Aug 6, 2019
- 8-K · Oct 29, 2019
- 10-Q · Nov 5, 2019
- 8-K · Jan 31, 2020
- 8-K · Feb 5, 2020
- 10-K · Feb 26, 2020
- 8-K · Apr 28, 2020
- 10-Q · May 6, 2020
- 8-K · May 29, 2020
- 8-K · Jun 24, 2020
- 8-K · Jul 31, 2020
- 10-Q · Aug 5, 2020
- 8-K · Oct 27, 2020
- 10-Q · Nov 5, 2020
- 8-K · Feb 1, 2021
- 8-K · Feb 4, 2021
- 8-K · Feb 4, 2021
- 10-K · Feb 25, 2021
- 8-K · Mar 24, 2021
- 8-K · Mar 26, 2021
- 8-K · Apr 29, 2021
- 8-K · May 5, 2021
- 10-Q · May 5, 2021
- 8-K · May 27, 2021
- 8-K · Jun 3, 2021
- 8-K · Jun 21, 2021
- 8-K · Jul 29, 2021
- 10-Q · Aug 9, 2021
- 8-K · Aug 20, 2021
- 8-K · Oct 28, 2021
- 10-Q · Nov 5, 2021
- 8-K · Dec 10, 2021
- 8-K · Feb 3, 2022
- 10-K · Feb 25, 2022
- 8-K · Mar 25, 2022
- 8-K · Apr 21, 2022
- 8-K · Apr 28, 2022
- 10-Q · May 5, 2022
- 8-K · May 26, 2022
- 8-K · Jul 28, 2022
- 10-Q · Aug 5, 2022
- 8-K · Oct 27, 2022
- 10-Q · Nov 3, 2022
- 8-K · Feb 2, 2023
- 10-K · Feb 24, 2023
- 8-K · Apr 27, 2023
- 10-Q · May 5, 2023
- 8-K · May 17, 2023
- 8-K · May 26, 2023
- 8-K · Aug 1, 2023
- 10-Q · Aug 7, 2023
- 8-K · Oct 26, 2023
- 10-Q · Nov 3, 2023
- 8-K · Nov 28, 2023
- 8-K · Feb 1, 2024
- 8-K · Feb 20, 2024
- 10-K · Feb 26, 2024
- 10-K/A · Apr 11, 2024
- 8-K · Apr 25, 2024
- 10-Q · May 3, 2024
- 8-K · May 30, 2024
- 8-K · Jul 30, 2024
- 10-Q · Aug 5, 2024
- 8-K · Oct 31, 2024
- 10-Q · Nov 6, 2024
- 8-K · Nov 22, 2024
- 8-K · Feb 4, 2025
- 10-K · Feb 25, 2025
- 8-K · Apr 24, 2025
- 10-Q · May 2, 2025
- 8-K · May 29, 2025
- 8-K · Jul 29, 2025
- 10-Q · Aug 5, 2025
- 8-K · Sep 9, 2025
- 8-K · Oct 30, 2025
- 10-Q · Nov 5, 2025
- 8-K · Dec 4, 2025
- 8-K · Feb 3, 2026
- 10-K · Feb 24, 2026
- 8-K · Apr 30, 2026
- 10-Q · May 4, 2026
- 8-K · May 22, 2026
- 8-K · May 28, 2026
- 8-K · Aug 4, 2026
- 10-Q · Aug 7, 2026
- 8-K · Oct 13, 2026
- 8-K · Oct 29, 2026
- 10-Q · Nov 4, 2026
- 8-K · Nov 18, 2026
Merck 8-K Report, Executive Changes (Nov 18, 2026)
This 8-K filing from Merck & Co., Inc. (MRK) primarily announces changes within its Board of Directors. Long-serving board member Thomas H. Glocer has notified the Company of his intention to retire from the Board at the 2027 Annual Meeting of Shareholders. This transition is not attributed to any disagreements with the Company's operations or policies. Concurrently, the independent members of the Board have appointed Douglas M. Baker, Jr. as the new independent lead director, effective January 1, 2027, succeeding Mr. Glocer in this capacity. Mr. Baker brings extensive experience in corporate governance, global marketing, sales, and operations from his previous role as CEO of Ecolab Inc. This leadership transition within the Board is a key focus of this report for investors.
Merck 8-K Report, Financial Results (Oct 29, 2026)
Merck & Co., Inc. (MRK) reported strong third-quarter 2026 financial results, driven by continued robust sales growth in its oncology and animal health segments, alongside contributions from other key products like WINREVAIR. Total worldwide sales reached $18.1 billion, a 5% increase year-over-year, with KEYTRUDA and KEYTRUDA QLEX sales showing a significant 6% rise to $8.6 billion. WINREVAIR demonstrated exceptional growth, soaring by 93% to $694 million. The company also highlighted substantial progress in its diverse pipeline, particularly in oncology, with key data presentations at the ESMO Congress 2026 and regulatory milestones such as the U.S. FDA's acceptance of a priority review for sacituzumab tirumotecan (sac-TMT) in endometrial cancer. Merck has narrowed and raised its full-year 2026 financial outlook, now expecting sales between $66.8 billion and $67.3 billion and non-GAAP EPS between $2.77 and $2.82, reflecting confidence in its ongoing growth trajectory and pipeline advancements.
Merck 8-K Report, Executive Changes (Oct 13, 2026)
Merck & Co., Inc. (NYSE: MRK) filed a Form 8-K on October 13, 2026 to report the election of Paul J. Diaz to its Board of Directors, effective November 1, 2026. Diaz, a managing partner at Cressey & Company and former CEO of Myriad Genetics and Kindred Healthcare, will join the Audit Committee and the Research Committee. With his addition, the board will grow to 14 members, and he will stand for shareholder election at the May 2027 annual meeting. For investors, this is a governance-level event rather than a financial one. The filing contains no earnings, guidance, financing, or material operational disclosures. The appointment of an experienced healthcare executive to the Audit Committee is a modest positive for board oversight of financial reporting and internal controls, and his seat on the Research Committee adds healthcare leadership experience to oversight of the company's pipeline. Diaz's compensation will follow Merck's standard non-employee director program, as described in the April 8, 2026 proxy statement, so no new compensation arrangement was disclosed. The company also states that Diaz has no arrangements or understandings with any other person regarding his election and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K. Overall, the filing is routine and unlikely to have a direct effect on the stock price or the company's near-term financial outlook.
Merck 8-K Report, Financial Results (Aug 4, 2026)
Merck & Co. (MRK) reported second-quarter 2026 results on August 4, 2026, with worldwide sales of $16.6 billion, up 5% (4% excluding FX). Growth was led by KEYTRUDA/KEYTRUDA QLEX ($8.4 billion, up 5%, including $463 million of initial KEYTRUDA QLEX sales), WINREVAIR ($588 million, up 75%), and Animal Health ($1.8 billion, up 8%). Gross margin compressed on a GAAP basis to 73.5% from 77.5%, and non-GAAP to 81.1% from 82.2%, reflecting higher amortization and inventory write-downs. The headline result was a GAAP loss of $0.54 per share and a non-GAAP loss of $0.13 per share, driven by a $2.31 per share (about $5.7 billion) one-time R&D charge for the acquisition of Terns Pharmaceuticals, which carried no tax benefit. The full-year 2026 sales outlook was narrowed and raised to $66.3-$67.3 billion from $65.8-$67.0 billion. Non-GAAP EPS guidance, however, fell sharply to $2.66-$2.76 from $5.04-$5.16. That reduction reflects one-time charges of $3.62 per share for the Cidara acquisition and $2.31 per share for Terns, plus about $0.12 per share of financing and MK-4208 advancement costs. The non-GAAP effective tax rate guidance rose to 35.0%-36.0% from 23.5%-24.5%, because the acquisition charges are not tax-deductible. Non-GAAP operating expenses are now guided to $42.0-$42.7 billion, up from $36.0-$36.8 billion, largely due to these one-time R&D charges. Pipeline news was substantial. The FDA approved LIPFENDRA (enlicitide), the first once-daily oral PCSK9 inhibitor, and several KEYTRUDA combination approvals were granted. The company also announced positive Phase 3 TroFuse-005 data for sac-TMT in endometrial cancer and positive ATLAS-UC data for tulisokibart, while the tulisokibart SSc-ILD study failed its primary endpoint and will be discontinued. Investors should weigh strong top-line and launch momentum against the sharp near-term EPS reset, the continued KEYTRUDA patent-cycle transition, and the ongoing cost of business development.
Merck 8-K Report, Shareholder Vote Results (May 28, 2026)
This 8-K filing from Merck & Co., Inc. (MRK) reports on the outcomes of its Annual Meeting of Shareholders held on May 26, 2026. The primary focus of the filing is the voting results on several key corporate matters. Importantly, all director nominees were elected by a substantial majority of votes cast, indicating continued shareholder confidence in the current board's leadership. Shareholders also approved the compensation of named executive officers on a non-binding advisory basis and ratified the appointment of the company's independent registered public accounting firm for 2026, with strong support for both proposals. However, the filing also highlights shareholder sentiment on ESG-related matters. Two shareholder proposals, one concerning a report on DEI risks in federal contracting and another on healthcare coverage gaps, received a very small percentage of 'FOR' votes relative to 'AGAINST' votes, suggesting limited shareholder backing for these specific initiatives at this time. Similarly, a proposal regarding political contributions also saw a significant majority vote against it. Investors should note the strong approval for governance and executive compensation matters, alongside the clear shareholder rejection of the presented ESG-focused proposals.
Merck 8-K Report, Corporate Update (May 22, 2026)
Merck & Co., Inc. (MRK) has filed an 8-K report detailing the successful closing of a significant underwritten public offering of various debt securities on May 22, 2026. The offering collectively raised substantial capital through the issuance of Floating Rate Notes due 2028 and fixed-rate notes maturing in 2028, 2031, 2033, 2036, 2046, and 2056, with aggregate principal amounts totaling $7.0 billion. This debt issuance, conducted under Merck's existing shelf registration statement, indicates the company's proactive capital management and its ability to access public debt markets to fund its operations, potential investments, or refinance existing obligations. The diverse maturity profile of the notes suggests a strategy to manage its debt obligations over the long term and potentially take advantage of prevailing interest rate conditions. Investors should monitor how these funds are deployed and their impact on Merck's financial leverage and future growth initiatives.
Merck 8-K Report, Financial Results (Apr 30, 2026)
Merck & Co. (MRK) reported first-quarter 2026 sales of $16.3 billion, up 5% reported and 3% excluding foreign exchange, driven by Keytruda/Keytruda Qlex ($8.0 billion, up 12%), WINREVAIR ($525 million, up 88%), and Animal Health ($1.8 billion, up 13%). However, GAAP and non-GAAP results were heavily depressed by a one-time $9.0 billion charge ($3.62 per share) for the acquisition of Cidara Therapeutics, producing a GAAP loss per share of $1.72 and a non-GAAP loss per share of $1.28, compared with GAAP EPS of $2.01 and non-GAAP EPS of $2.22 a year earlier. Excluding the Cidara charge, the underlying business trends are more meaningful: non-GAAP gross margin was 81.9% versus 82.2%, and continued growth in oncology, cardiometabolic, and animal health offset declines in Gardasil (down 19%, largely on lower China demand), Januvia/Janumet (down 28%), and Lagevrio (down 73%). Management narrowed and raised the midpoint of its full-year 2026 guidance, now calling for sales of $65.8 billion to $67.0 billion (prior $65.5 billion to $67.0 billion) and non-GAAP EPS of $5.04 to $5.16 (prior $5.00 to $5.15), both including the Cidara charge. Importantly, the outlook excludes the pending acquisition of Terns Pharmaceuticals, which is expected to close in May 2026 and carry a one-time charge of approximately $5.8 billion, or about $2.35 per share, plus an estimated $0.12 per share of further EPS drag over the remainder of 2026 from TERN-701 investment and financing costs. Investors will need to weigh this near-term earnings dilution against the strategic push to diversify the portfolio beyond Keytruda, which faces biosimilar and patent-cycle risks over time. Pipeline news was mixed. Positive developments included FDA approval of IDVYNSO (an oral once-daily HIV regimen), approval of Keytruda for platinum-resistant ovarian cancer, and positive Phase 3 KEYNOTE-B15 results with a priority review (PDUFA August 17, 2026). Setbacks included several Phase 3 readouts that failed to reach statistical significance, notably LITESPARK-012 in renal cell carcinoma, KEYNOTE-975 in esophageal cancer, and KEYNOTE-866 in muscle-invasive bladder cancer. Upcoming catalysts include multiple PDUFA dates in June, August, and October 2026 and an Oncology Investor Event on June 1, 2026.
Merck 8-K Report, Financial Results (Feb 3, 2026)
Merck & Co. (MRK) reported fourth-quarter and full-year 2025 results on February 3, 2026. Fourth-quarter worldwide sales were $16.4 billion, up 5% (4% ex-FX), while full-year sales were $65.0 billion, up 1% (2% ex-FX). Growth was led by KEYTRUDA/KEYTRUDA QLEX ($31.7 billion, up 7%) and newer launches including WINREVAIR ($1.4 billion, up from $419 million) and CAPVAXIVE ($759 million). These gains were offset by a 39% decline in GARDASIL/GARDASIL 9 to $5.2 billion, driven by lower China demand and Japan's catch-up program. Animal Health grew 8% to $6.4 billion. Full-year non-GAAP EPS was $8.98 (up 17%) and GAAP EPS was $7.28 (up 8%), with the GAAP figure absorbing a $0.20 per-share charge for business development deals. The more consequential news for investors is the 2026 outlook. Merck guided to sales of $65.5 to $67.0 billion and non-GAAP EPS of $5.00 to $5.15. That EPS guide is sharply lower than 2025 because it includes a one-time charge of roughly $3.65 per share (about $9.0 billion) tied to the acquisition of Cidara Therapeutics, plus about $0.30 per share of related financing and operating costs. Excluding the Cidara charge, the implied underlying earnings trajectory is considerably more stable. The outlook also assumes no additional significant business development transactions, which is consistent with Merck's past practice. Management highlighted pipeline progress, including 18 positive Phase 3 readouts in 2025, FDA Commissioner's National Priority Vouchers for enlicitide and sac-TMT, and a U.S. government agreement that delays Section 232 tariffs for three years in exchange for more than $70 billion in committed U.S. capital and R&D spending. Key risks for investors are the continued erosion of GARDASIL, KEYTRUDA's dependence on its ongoing lifecycle and the timing of its loss of exclusivity, the rising interest expense and FX losses that pushed other expense higher, and the execution risk of integrating Verona Pharma and Cidara. Because this filing furnishes the press release under Item 2.02, the content is not deemed filed under Section 18 of the Exchange Act.
Merck 8-K Report, Corporate Update (Dec 4, 2025)
Merck & Co., Inc. (MRK) announced the successful closing of a significant underwritten public offering of debt securities on December 4, 2025. The offering comprised a total of eight distinct tranches of notes, raising a substantial amount of capital for the company. This move indicates Merck's strategy to secure long-term financing and potentially fund its ongoing research and development, capital expenditures, or general corporate purposes. The issuance involved notes with varying maturity dates, ranging from 2029 to 2065, and a mix of floating rate and fixed-rate instruments, suggesting a diversified approach to debt management. Investors should note that this offering represents a material increase in Merck's outstanding debt. While the specific use of proceeds is not detailed in this 8-K filing, such debt issuances are typically aimed at strengthening the company's financial flexibility and supporting its strategic initiatives. The diverse maturity profile suggests an effort to manage interest rate risk and balance short-term and long-term financing needs. Further analysis of Merck's financial statements and future disclosures will be necessary to fully understand the impact of this debt issuance on the company's capital structure and profitability.
Merck 8-K Report, Financial Results (Oct 30, 2025)
Merck & Co. (MRK) reported third-quarter 2025 results with total sales of $17.3 billion, up 4% nominally and 3% excluding foreign exchange. Growth was led by KEYTRUDA, which rose 10% to $8.1 billion (8% ex-FX), and WINREVAIR, which more than doubled to $360 million. GAAP EPS was $2.32 and non-GAAP EPS was $2.58, with both including a $0.10 per-share charge for a milestone payment to LaNova tied to the MK-2010 technology transfer. GAAP net income rose 83% year over year, though that comparison benefits from a 2024 quarter that carried roughly $0.79 per share in aggregate business development charges (EyeBio, MK-1045/Curon, and a Daiichi Sankyo-related item). Gross margin expanded to 77.7% GAAP and 81.9% non-GAAP. GARDASIL/GARDASIL 9 was the main drag, falling 24% to $1.7 billion on lower demand in China, and LAGEVRIO declined 64%. Management raised and narrowed its full-year 2025 non-GAAP EPS guidance to $8.93–$8.98 from $8.87–$8.97, and raised the sales outlook to $64.5–$65.0 billion from $64.3–$65.3 billion. The EPS raise reflects a roughly $0.09 benefit from an amended AstraZeneca Koselugo agreement and operational improvements, partly offset by about $0.04 of dilution from the Verona Pharma acquisition, which closed in October 2025. Management also reiterated a commitment of more than $70 billion to U.S. manufacturing and R&D beginning in 2025, excluding future business development. For investors, the key takeaways are the strong KEYTRUDA franchise (with a subcutaneous KEYTRUDA QLEX now approved across solid tumor indications), the rapid WINREVAIR ramp, and the Verona and Koselugo-related guidance changes. Offsetting these are the GARDASIL China decline and the ongoing exposure to a patent cliff for KEYTRUDA in the later part of the decade, which the filing does not discuss directly. The updated guidance does not assume additional significant business development transactions, and management plans an investor event at AHA on November 9, 2025.
Merck 8-K Report, Corporate Update (Sep 9, 2025)
Merck & Co., Inc. (MRK) announced the successful closing of a substantial underwritten public offering of debt securities on September 9, 2025. This offering comprises various tranches of notes with aggregate principal amounts totaling $6.5 billion, including floating rate notes and fixed-rate notes with maturities ranging from 2027 to 2055. The proceeds from this offering will likely be used to fund general corporate purposes, potentially including research and development, acquisitions, or refinancing existing debt. Investors should note that this issuance increases the company's overall debt leverage. The issuance was conducted under the company's effective Form S-3ASR registration statement, indicating Merck's established access to capital markets. The specific terms of the notes, including coupon rates and maturity dates, are detailed in the filing. The inclusion of various maturity dates suggests a strategy to manage interest rate risk and maintain a balanced debt maturity profile. Investors will want to monitor how these new debt obligations impact Merck's financial leverage ratios and cash flow from operations.
Merck 8-K Report, Financial Results (Jul 29, 2025)
Merck (MRK) reported second-quarter 2025 results on July 29, 2025, with total sales of $15.8 billion, down 2% both nominally and excluding foreign exchange. The top-line decline was driven by Gardasil/Gardasil 9, which fell 55% to $1.1 billion on lower demand in China, and by the absence of SIMPONI, which reverted to Johnson & Johnson in October 2024. KEYTRUDA was the standout performer at $8.0 billion, up 9%, and WINREVAIR reached $336 million as it continued its U.S. launch. Animal Health grew 11% to $1.6 billion. GAAP EPS was $1.76 and non-GAAP EPS was $2.13, versus $2.14 and $2.28 a year earlier. Both figures include a $0.07 charge for the Hengrui Pharma license closing. The most consequential disclosure is the new multiyear optimization initiative, which targets roughly $3.0 billion in annual cost savings by the end of 2027, to be fully reinvested in growth areas. Within it, a 2025 Restructuring Program carries cumulative pretax costs of about $3.0 billion (roughly 60% cash) and is expected to deliver $1.7 billion of annual savings, largely realized by end-2027. Merck recorded $649 million of restructuring charges related to this program in Q2. Management also narrowed full-year 2025 guidance: sales of $64.3 to $65.3 billion and non-GAAP EPS of $8.87 to $8.97, which includes about $0.16 of one-time charges. The outlook excludes the pending Verona Pharma acquisition, expected to close in Q4 2025 for about $10 billion. Investors should weigh the strong KEYTRUDA and pipeline momentum against the Gardasil erosion and the near-term cost of the restructuring. Pipeline news in the quarter was mixed. Several Phase 3 readouts were positive, including the CORALreef trials of enlicitide and KEYNOTE-B96, but KEYNOTE-937 and LEAP-014 did not reach statistical significance. Upcoming catalysts include the WINREVAIR label-update PDUFA date of October 25, 2025, and the doravirine/islatravir PDUFA date of April 28, 2026.
Merck 8-K Report, Shareholder Vote Results (May 29, 2025)
Merck & Co., Inc. (MRK) has filed an 8-K report detailing the results of its Annual Meeting of Shareholders held on May 27, 2025. The filing primarily focuses on the voting outcomes of several key proposals presented to shareholders. All director nominees were overwhelmingly elected, indicating strong shareholder confidence in the current board's composition and leadership. Similarly, the appointment of the Company's independent registered public accounting firm for 2025 received substantial ratification. Notably, the advisory vote to approve the compensation of named executive officers also passed with significant support. However, several shareholder proposals, including those related to human rights impact assessments, tax transparency, revisiting DEI goals in executive pay, and civil liberties in advertising, did not receive majority support and were voted down. These outcomes suggest shareholders are largely aligned with the company's current governance and executive compensation practices, while also signaling a divergence of opinion on specific ESG-related initiatives proposed by shareholders.
Merck 8-K Report, Financial Results (Apr 24, 2025)
Merck reported first-quarter 2025 results on April 24, 2025, with worldwide sales of $15.5 billion, down 2% from the prior year but up 1% excluding foreign exchange. The top-line picture was mixed: KEYTRUDA grew 4% to $7.2 billion (6% ex-FX) and WINREVAIR launched to $280 million in its first full year of U.S. uptake, while GARDASIL/GARDASIL 9 fell 41% to $1.3 billion, driven mainly by lower demand in China. Animal Health (+5%) and Other Revenues (+17%, helped by out-licensing payments) were bright spots. Profitability held up well, with GAAP EPS of $2.01 (up 7%) and non-GAAP EPS of $2.22 (up 7%, or 12% ex-FX). Non-GAAP gross margin improved to 82.2% from 81.2%. Management maintained full-year 2025 sales guidance of $64.1 billion to $65.6 billion, but lowered non-GAAP EPS guidance to $8.82 to $8.97 from $8.88 to $9.03. The cut reflects a one-time charge of about $0.06 per share tied to an upfront payment for the exclusive license of Hengrui Pharma's oral Lp(a) inhibitor, expected to close in the second quarter of 2025. Excluding that charge, the EPS outlook would have been unchanged. The outlook also absorbs roughly $200 million of incremental tariff costs and about 1% of negative FX impact on sales. Guidance continues to include an expected $0.09 per share charge tied to the LaNova MK-2010 technology-transfer milestone. For investors, the key items to monitor are the trajectory of GARDASIL in China, the pace of WINREVAIR and KEYTRUDA uptake, upcoming regulatory decisions (subcutaneous pembrolizumab PDUFA date of September 23, 2025, and KEYNOTE-689 head and neck PDUFA date of June 23, 2025), and the execution of Merck's pipeline business development and U.S. manufacturing investments. The company's guidance does not assume additional significant business development deals.
Merck 8-K Report, Financial Results (Feb 4, 2025)
Merck & Co. (MRK) reported fourth-quarter and full-year 2024 results on February 4, 2025, showing strong top-line momentum led by KEYTRUDA. Fourth-quarter worldwide sales rose 7% to $15.6 billion (9% excluding foreign exchange), and full-year sales grew 7% to $64.2 billion (10% ex-FX). KEYTRUDA was the standout, with full-year sales up 18% to $29.5 billion, while GARDASIL/GARDASIL 9 declined 3% to $8.6 billion, driven largely by weaker demand in China. WINREVAIR launched in the second quarter of 2024 and reached $419 million in its first partial year, and Animal Health grew 4% to $5.9 billion. GAAP results were distorted by business development charges. Full-year GAAP EPS was $6.74 and non-GAAP EPS was $7.65, both including a net $1.28 per-share charge tied to licensing deals and collaborations. Fourth-quarter GAAP EPS was $1.48 and non-GAAP EPS was $1.72, including a $0.23 charge tied to the LaNova and Hansoh agreements. Year-over-year comparisons are heavily affected by the prior year's large charges and the 2023 Zetia settlement, so the non-GAAP figures are the more useful measure of underlying performance. Margin expansion was notable: non-GAAP gross margin reached 80.8% in both the fourth quarter and full year, reflecting favorable product mix, including lower royalty rates on KEYTRUDA and GARDASIL. For 2025, Merck guided to sales of $64.1 billion to $65.6 billion and non-GAAP EPS of $8.88 to $9.03. The outlook includes a roughly $0.09 per-share one-time charge for a $300 million LaNova milestone payment, and it reflects a temporary pause in GARDASIL shipments to China starting February 2025 through at least mid-year. The guidance also excludes any significant new business development deals, consistent with past practice. Pipeline news included positive ZENITH results for WINREVAIR (stopped early for overwhelming efficacy), positive Phase 3 data for subcutaneous pembrolizumab, and an FDA BLA acceptance for clesrovimab with a June 10, 2025 PDUFA date.
Merck 8-K Report, Executive Changes (Nov 22, 2024)
Merck & Co. (MRK) filed an 8-K on November 22, 2024 reporting two governance actions rather than financial results. First, the company announced that Surendralal L. "Lal" Karsanbhai, president and CEO of Emerson Electric Co. (NYSE: EMR), will join its Board of Directors effective January 1, 2025, expanding the board to 13 members. He will be appointed to both the Audit and Governance Committees and will stand for shareholder election in May 2025. He will receive standard non-employee director compensation, and the filing discloses no related-party transactions or special election arrangements. Second, on November 19, 2024, the Board adopted amended and restated by-laws that revise and update indemnification provisions for directors, officers, employees and agents, along with some non-substantive conforming changes. The filing describes these as updates to indemnification terms rather than changes to shareholder rights or corporate control provisions, though investors should review the full By-Laws (Exhibit 3.1) to confirm the specifics. For investors, neither item affects Merck's reported financials or guidance. The most notable element is the addition of an experienced industrial operator with audit committee responsibilities, which may be viewed as a positive for board oversight and operational perspective. The filing also contains standard forward-looking statement cautions referencing the company's 2023 Form 10-K.
Merck 8-K Report, Financial Results (Oct 31, 2024)
Merck's third-quarter 2024 results (8-K filed October 31, 2024) showed total sales of $16.7 billion, up 4% reported and 7% excluding foreign exchange, led by KEYTRUDA, which grew 17% to $7.4 billion (21% ex-FX). Growth was partially offset by declines in GARDASIL/GARDASIL 9 (down 11%, largely on lower demand in China), JANUVIA/JANUMET (down 42%) and LAGEVRIO (down 40%). Animal Health sales rose 6% to $1.5 billion, and WINREVAIR, launched in the U.S. in the second quarter, reached $149 million in sales. Earnings were depressed by business development charges. GAAP EPS was $1.24 versus $1.86 a year earlier, and non-GAAP EPS was $1.57 versus $2.13, with both figures including a net $0.79 per-share charge tied to the EyeBio and Curon acquisitions and a Daiichi Sankyo payment. Non-GAAP gross margin improved to 80.5% from 77.0%, reflecting favorable product mix and lower royalty rates on KEYTRUDA and GARDASIL. Full-year 2024 guidance was mixed. Sales guidance was narrowed to $63.6 to $64.1 billion from $63.4 to $64.4 billion, and the non-GAAP EPS range was lowered to $7.72 to $7.77 from $7.94 to $8.04, reflecting a net $0.24 per-share negative impact from the Curon and Daiichi Sankyo transactions. Management said the outlook assumes no additional significant business development transactions.
Merck 8-K Report, Financial Results (Jul 30, 2024)
Merck reported second-quarter 2024 results on July 30, 2024, with total sales of $16.1 billion, up 7% reported and 11% excluding foreign exchange. KEYTRUDA was the clear growth engine at $7.3 billion (up 16%, or 21% ex-FX), driven by earlier-stage indications such as triple-negative breast cancer and renal cell carcinoma. Profitability was strong: GAAP EPS was $2.14 versus a loss of $2.35 a year earlier, which included a $4.02 per share Prometheus charge, and non-GAAP EPS was $2.28. The quarter also benefited from a $259 million tax reserve release tied to the expiration of a statute of limitations for the 2019 tax year, which flattered the GAAP and non-GAAP tax lines and should be treated as non-recurring. The full-year 2024 sales outlook was raised and narrowed to $63.4 to $64.4 billion from $63.1 to $64.3 billion, despite a softer quarter for GARDASIL in China caused by distributor sell-out timing. However, non-GAAP EPS guidance was cut sharply to $7.94 to $8.04 from $8.53 to $8.65. The reduction reflects a one-time $1.3 billion (about $0.51 per share) charge for the EyeBio acquisition, plus about $0.26 per share for Harpoon and roughly $0.09 per share of financing and asset-advancement expense, and a higher expected non-GAAP tax rate of 15.5% to 16.5%. Investors should therefore read the EPS cut as largely acquisition-driven rather than a deterioration in underlying demand. On the pipeline side, the filing highlights the U.S. launch of WINREVAIR (over 1,000 patients treated by end of June), FDA approval of the CAPVAXIVE pneumococcal vaccine with a unanimous ACIP recommendation, positive Phase 2b/3 data for clesrovimab in infant RSV prevention, and a positive EU CHMP opinion for WINREVAIR. Offsetting pressures include continued erosion in JANUVIA/JANUMET (down 27% and 27% in the quarter, respectively, on U.S. pricing and generic competition), BRIDION, and LAGEVRIO, as well as the Argentine peso devaluation that weighed on reported growth.
Merck 8-K Report, Shareholder Vote Results (May 30, 2024)
Merck & Co., Inc. (MRK) filed an 8-K on May 29, 2024, detailing the results of its Annual Meeting of Shareholders held on May 28, 2024, and the closing of a significant debt offering. The shareholder meeting saw overwhelming approval for the election of all director nominees, the executive compensation plan (say-on-pay), and the ratification of the independent auditor. These strong votes indicate continued shareholder confidence in the company's leadership and financial oversight. In addition to the shareholder meeting outcomes, Merck announced on May 30, 2024, the successful closing of a public offering of €3.4 billion in aggregate principal amount of notes across four maturity tranches (2032, 2037, 2044, and 2054) by its subsidiary, MSD Netherlands Capital B.V. These notes are fully guaranteed by Merck & Co., Inc. This debt issuance provides the company with substantial capital, likely for general corporate purposes or strategic initiatives, and diversifies its funding sources. Investors should note the relatively low interest rates on these long-term notes, reflecting favorable market conditions for the company.
Merck 8-K Report, Financial Results (Apr 25, 2024)
Merck reported first-quarter 2024 sales of $15.8 billion, up 9% from the prior year (12% excluding foreign exchange). Growth was led by oncology and vaccines: KEYTRUDA sales rose 20% to $6.9 billion (24% excluding FX), and GARDASIL/GARDASIL 9 rose 14% to $2.2 billion (17% excluding FX). Diabetes was the main drag, with JANUVIA/JANUMET down 24%. GAAP EPS was $1.87 and non-GAAP EPS was $2.07, both including a $0.26 per-share charge for the Harpoon acquisition. The GAAP gross margin improved to 77.6% from 72.9%, mainly from product mix, lower royalty rates on KEYTRUDA and GARDASIL, and lower amortization of intangibles. Management raised and narrowed its full-year 2024 outlook. Sales are now expected at $63.1 billion to $64.3 billion (previously $62.7 billion to $64.2 billion), and non-GAAP EPS at $8.53 to $8.65 (previously $8.44 to $8.59). The guidance includes roughly 3% negative FX impact on sales and about $0.30 per share of negative FX impact on EPS, largely attributable to the Argentine peso. The outlook does not assume additional significant business development deals. Merck also completed the Harpoon acquisition and agreed to acquire Elanco's aqua business, and WINREVAIR received FDA approval for pulmonary arterial hypertension. For investors, the key points are the strength of the KEYTRUDA franchise, the upward revision to earnings guidance, and the pipeline catalysts ahead. Three FDA target action dates fall in the second quarter of 2024 (V116, KEYTRUDA in endometrial cancer, and patritumab deruxtecan), and an Oncology Investor Event is scheduled for June 3, 2024. Risks include continued declines in the diabetes franchise, generic competition in Europe and Asia Pacific, currency volatility, and the possibility of additional business development charges that the outlook excludes.
Merck 8-K Report, Executive Changes (Feb 20, 2024)
Merck & Co., Inc. (MRK) filed an 8-K on February 20, 2024, reporting the upcoming retirement of a key board member. Peter C. Wendell, a director since 2002 and a member of the Audit Committee, has announced his intention to retire from the Board of Directors at the Company's 2024 Annual Meeting of Shareholders on May 28, 2024. This departure is not attributed to any disagreements with the company's operations, policies, or practices, which suggests a smooth transition. While the retirement of a long-serving director is noteworthy, investors should note that the filing explicitly states no disagreements exist. The primary focus for investors remains on Merck's ongoing business performance, its product pipeline, and strategic initiatives. The upcoming annual meeting will be a key event to watch for further updates on board composition and leadership.
Merck 8-K Report, Financial Results (Feb 1, 2024)
Merck (MRK) reported fourth-quarter and full-year 2023 results on February 1, 2024. Full-year 2023 sales were $60.1 billion, up 1% reported and 4% excluding foreign exchange, with Keytruda ($25.0 billion, up 19%) and Gardasil/Gardasil 9 ($8.9 billion, up 29%) driving growth, offset by a 75% decline in COVID-19 antiviral LAGEVRIO to $1.4 billion. Profitability was sharply lower on a GAAP basis: full-year GAAP EPS fell to $0.14 from $5.71, largely due to $6.21 per share of business development charges (including a $5.5 billion Daiichi Sankyo collaboration charge in Q4 and $11.4 billion across the Prometheus and Imago acquisitions). Non-GAAP EPS was $1.51 versus $7.48 in 2022. Excluding these charges, the underlying business showed improved gross margin (non-GAAP 76.9%, up from 74.4%) and operational strength. The company also disclosed a new 2024 Restructuring Program, approved January 29, 2024, with cumulative pretax costs of about $4.0 billion through the end of 2031. Roughly 60% is non-cash accelerated depreciation tied to facility closures or divestitures, and the rest is largely cash facility shutdown costs. The program targets Human Health manufacturing as the pipeline shifts to new modalities and Animal Health manufacturing efficiency. Only $190 million was recorded in 2023, so the bulk of the charge will fall in future periods. For 2024, Merck guided to sales of $62.7 to $64.2 billion and non-GAAP EPS of $8.44 to $8.59, which includes roughly $0.26 per share of one-time Harpoon acquisition charges and about $0.25 per share of foreign exchange headwind. Investors will focus on whether Keytruda and Gardasil growth can offset the expected LAGEVRIO decline, the pace of R&D spending tied to recent acquisitions, and the cash cost of the new restructuring program.
Merck 8-K Report, Executive Changes (Nov 28, 2023)
Merck & Co., Inc. (MRK) filed an 8-K on November 28, 2023, to announce a key executive transition within its finance department. Rita Karachun, Senior Vice President Finance – Global Controller and principal accounting officer, has resigned effective December 4, 2023, as she plans to retire in 2024. The company has assured investors that Ms. Karachun's departure is not a result of any disagreements concerning the company's operations, policies, or practices. Concurrently, Merck has appointed Dalton E. Smart III to succeed Ms. Karachun as Senior Vice President Finance – Global Controller and principal accounting officer, also effective December 4, 2023. Mr. Smart has a long tenure with Merck, most recently serving as Assistant Controller since September 2023 and previously holding roles in Internal Audit and Audit leadership. This transition appears to be an internal promotion, intended to ensure continuity in financial oversight.
Merck 8-K Report, Financial Results (Oct 26, 2023)
Merck reported third-quarter 2023 results with total sales of $16.0 billion, up 7% year over year (9% excluding foreign exchange). Growth was led by oncology and vaccines: KEYTRUDA sales rose 17% to $6.3 billion and GARDASIL/GARDASIL 9 rose 13% to $2.6 billion. LAGEVRIO contributed $640 million (up 47%). GAAP EPS was $1.86, up 45%, while non-GAAP EPS was $2.13, up 15%. The improvement was partly offset by unfavorable foreign exchange and by the absence of 2022 charges tied to Moderna, Orna and Orion agreements and intangible asset impairments. The most important item for investors is the sharply lower full-year 2023 non-GAAP EPS guidance, now $1.33 to $1.38, down from $2.95 to $3.05. The cut reflects a $5.5 billion ($1.70 per share) pretax upfront charge for the Daiichi Sankyo ADC collaboration, along with acquisition-related charges and roughly 6 percentage points of foreign exchange headwind. Excluding these items, management says the business was approximately $0.15 per share stronger than previously expected. Sales guidance was raised to $59.7 to $60.2 billion from $58.6 to $59.6 billion, and the non-GAAP effective tax rate guidance rose to 39% to 40% from 30.5% to 31.5%, driven by business development charges. Pipeline progress was also significant. The FDA approved KEYTRUDA for resectable early-stage NSCLC, and priority reviews were granted for sotatercept (PDUFA date March 26, 2024), KEYTRUDA in cervical cancer, and WELIREG in RCC. Merck also started new Phase 3 programs in 2023, including the oral PCSK9 inhibitor MK-0616. Investors should watch the Keytruda growth trajectory, the impact of the Daiichi Sankyo deal on future R&D spending, and the upcoming regulatory decisions.
Merck 8-K Report, Financial Results (Aug 1, 2023)
Merck reported second-quarter 2023 results on August 1, 2023, with total sales of $15.0 billion, up 3% reported and 7% excluding foreign exchange (11% excluding LAGEVRIO, the COVID antiviral). The headline is a GAAP loss of $2.35 per share, versus EPS of $1.55 a year earlier. The loss is driven by a $10.2 billion (about $4.02 per share) one-time charge for the acquisition of Prometheus Biosciences, which is recorded in R&D and carries no tax benefit. Non-GAAP loss per share was $2.06, compared with non-GAAP EPS of $1.87 in the prior-year quarter. Underlying demand was strong: KEYTRUDA sales rose 19% to $6.3 billion, and GARDASIL/GARDASIL 9 rose 47% to $2.5 billion, with the core oncology and vaccine franchises carrying the growth. Investors should look past the reported loss to the operating trends. Gross margin improved to 73.2% GAAP and 76.6% non-GAAP, helped by lower low-margin LAGEVRIO sales and favorable product mix. LAGEVRIO fell 83% to $203 million, and this decline is the main drag on reported growth. Management raised and narrowed its full-year 2023 sales guidance to $58.6 billion to $59.6 billion, including about $1.0 billion of LAGEVRIO. It lowered the non-GAAP EPS outlook to $2.95 to $3.05, a range that now reflects the Prometheus charge and about $0.24 per share of underlying business strength. Foreign exchange is a meaningful headwind, costing about 2 points of sales growth and about 5 points of EPS. The quarter also advanced the pipeline. Merck completed the Prometheus acquisition, which adds MK-7240 (formerly PRA-023) to its immunology franchise. It also submitted a Biologics License Application for sotatercept in pulmonary arterial hypertension, reported positive Phase 3 data for the V116 pneumococcal vaccine, and presented KEYTRUDA data across earlier-stage cancers. Key risks include the post-COVID decline in LAGEVRIO, erosion of JANUVIA/JANUMET from generic competition, currency movements, and the R&D spending implied by the Prometheus deal.
Merck 8-K Report, Shareholder Vote Results (May 26, 2023)
Merck & Co., Inc. (MRK) filed an 8-K on May 25, 2023, detailing the results of its Annual Meeting of Shareholders held on May 23, 2023. The primary focus of the filing is the shareholder votes on various proposals, including the election of directors, executive compensation, and several shareholder-submitted proposals. All director nominees were overwhelmingly elected, and shareholders approved the appointment of the independent registered public accounting firm for 2023 with strong support. Investors will note that shareholders overwhelmingly supported an annual advisory vote on executive compensation and favored an "one year" frequency for future advisory votes on executive compensation. However, a significant number of shareholder proposals, concerning topics such as operations in China, access to COVID-19 products, political spending, patents, congruency reports, and board independence, were largely rejected by the majority of votes cast, indicating continued alignment between the board's recommendations and the majority shareholder sentiment on these specific issues.
Merck 8-K Report, Corporate Update (May 17, 2023)
Merck & Co., Inc. (MRK) filed an 8-K on May 17, 2023, to report the closing of a significant underwritten public offering of senior notes. The company successfully raised a total of $6.25 billion across six different tranches, with maturities ranging from 2028 to 2063 and coupon rates varying from 4.050% to 5.150%. This offering indicates Merck's proactive approach to managing its capital structure and potentially funding future growth initiatives or refinancing existing debt. Investors should note that this filing is primarily informational, detailing the debt issuance. While it does not directly disclose new operational or financial performance data, the ability to raise such a substantial amount of capital at these rates suggests continued investor confidence in Merck's financial stability and long-term prospects. The specific use of proceeds is not detailed in this filing, which is common for debt offerings of this nature.
Merck 8-K Report, Financial Results (Apr 27, 2023)
Merck reported first-quarter 2023 results on April 27, 2023, with total sales of $14.5 billion, down 9% from $15.9 billion a year earlier. The decline was driven by a 88% drop in COVID-19 antiviral LAGEVRIO sales ($392 million vs. $3.2 billion). Excluding LAGEVRIO, sales grew 11%, and excluding LAGEVRIO and foreign exchange, growth was 15%. The core franchise remained strong: KEYTRUDA rose 20% to $5.8 billion and GARDASIL/GARDASIL 9 rose 35% to $2.0 billion. Non-GAAP EPS was $1.40 versus $2.14 a year earlier, and GAAP EPS was $1.11 versus $1.70. The year-over-year EPS declines were largely due to $0.52 per share of charges tied to the Imago BioSciences acquisition and the Kelun-Biotech collaboration, plus lower LAGEVRIO sales and unfavorable currency effects. GAAP results also carried a $573 million charge for Zetia antitrust settlements. Management raised and narrowed its full-year 2023 sales guidance to $57.7–$58.9 billion, including about $1.0 billion of LAGEVRIO sales, and raised non-GAAP EPS guidance to $6.88–$7.00. GAAP EPS guidance was lowered to $5.85–$5.97 because of the Zetia charge. The outlook excludes the pending Prometheus Biosciences acquisition, which is expected to close in Q3 2023 for $10.8 billion in equity value. Merck expects that deal to produce a one-time charge of roughly $10.3 billion, or about $4.00 per share, and an ongoing EPS drag of about $0.25 in the first 12 months after close. The quarter also brought pipeline news, including positive Phase 3 STELLAR data for sotatercept in pulmonary arterial hypertension, positive Phase 2b data for the oral PCSK9 inhibitor MK-0616, and an FDA accelerated approval of KEYTRUDA with Padcev for urothelial carcinoma. Investors should weigh the strong underlying growth in KEYTRUDA and vaccines against the near-term earnings impact of the Prometheus transaction and the fading LAGEVRIO contribution.
Merck 8-K Report, Financial Results (Feb 2, 2023)
Merck reported fourth-quarter and full-year 2022 results on February 2, 2023, showing strong top-line momentum led by oncology and vaccines. Full-year 2022 worldwide sales rose 22% to $59.3 billion (12% growth excluding LAGEVRIO, and 15% excluding both LAGEVRIO and foreign exchange). KEYTRUDA grew 22% to $20.9 billion and GARDASIL/GARDASIL 9 grew 22% to $6.9 billion. Fourth-quarter sales were $13.8 billion, up 2% reported but up 8% excluding foreign exchange. Results are presented on a continuing operations basis, excluding Organon, which was spun off in 2021. Earnings were weaker than the top line suggests. Full-year GAAP EPS from continuing operations was $5.71, up 17%, while non-GAAP EPS was $7.48, up 39%. The fourth-quarter GAAP EPS of $1.18 fell 22% year over year, and non-GAAP EPS of $1.62 fell 10%. Fourth-quarter results were pressured by lower 2021 tax rates, unfavorable foreign exchange, losses on equity investments versus gains a year earlier, and intangible asset impairment charges of $780 million, largely related to nemtabrutinib. Full-year 2022 EPS was also reduced by $0.22 from collaboration and licensing charges with Moderna, Orna and Orion. Non-GAAP results in 2022 no longer exclude these collaboration charges, and 2021 has been recast to match. The 2023 outlook calls for sales of $57.2 billion to $58.7 billion, which includes about $1.0 billion of LAGEVRIO sales, a sharp decline from 2022. GAAP EPS is guided to $5.86 to $6.01 and non-GAAP EPS to $6.80 to $6.95. The guidance absorbs about $0.53 per share of charges from the Imago acquisition (closed January 2023) and the Kelun-Biotech license, which together add roughly $1.4 billion of R&D expense. The outlook does not assume further significant business development deals.
Merck 8-K Report, Financial Results (Oct 27, 2022)
Merck's Q3 2022 results showed strong top-line momentum: worldwide sales rose 14% to $15.0 billion (18% excluding foreign exchange), led by KEYTRUDA (+20% to $5.4 billion) and GARDASIL/GARDASIL 9 (+15% to $2.3 billion), with LAGEVRIO contributing $436 million. GAAP EPS from continuing operations was $1.28, down 29% year over year, while non-GAAP EPS rose 4% to $1.85. The GAAP decline was driven largely by acquisition- and divestiture-related costs (including collaboration and licensing charges tied to Moderna, Orna and Orion), an $887 million intangible asset impairment related to the ArQule acquisition, and $350 million of net losses on equity securities. Management raised its full-year 2022 sales outlook to $58.5-59.0 billion (about 20-21% growth) and narrowed non-GAAP EPS guidance to $7.32-7.37, but lowered GAAP EPS guidance to $5.68-5.73. The non-GAAP raise was partly offset by a $250 million option payment to Moderna and roughly 4% negative FX impact. Leadership change was also disclosed. Kenneth C. Frazier, Executive Chairman, will retire from the Board effective November 30, 2022, and CEO Robert M. Davis was elected by the Board to succeed him as Chairman effective December 1, 2022. For investors, this is a governance transition rather than an operational change, since Davis already leads the company and Frazier had served as executive chairman since July 2021. Key near-term watch items include the GAAP-to-non-GAAP gap, which widened materially as Merck stopped excluding upfront and milestone payments from non-GAAP results in 2022, pipeline catalysts such as sotatercept (STELLAR Phase 3 positive), the Lynparza PROpel FDA decision expected in Q4 2022, and the continued pace of LAGEVRIO sales as COVID-19 antiviral demand evolves.
Merck 8-K Report, Financial Results (Jul 28, 2022)
Merck reported second-quarter 2022 results on July 28, 2022 that were strong on the top line and raised the low end of its sales outlook. Worldwide sales rose 28% to $14.6 billion (31% excluding foreign exchange), with LAGEVRIO contributing $1.2 billion. Excluding LAGEVRIO, growth was 18%, and excluding LAGEVRIO and FX it was 20%. KEYTRUDA grew 26% to $5.3 billion and GARDASIL/GARDASIL 9 grew 36% to $1.7 billion. Growth was broad across oncology, vaccines and hospital acute care, with COVID-19 recovery providing a tailwind because the prior-year quarter was depressed. Profitability was more mixed. GAAP EPS was $1.55 versus $0.48 a year earlier, but that comparison is distorted by the prior-year $1.7 billion Pandion acquisition charge. Non-GAAP EPS was $1.87. GAAP results were weighed down by net unrealized losses on equity investments, higher pension settlement costs, higher acquisition-related costs and a lower non-GAAP gross margin (74.7%, down from 76.5%) caused by LAGEVRIO profit sharing with Ridgeback. Management raised and narrowed full-year sales guidance to $57.5-58.5 billion (18-20% growth), a more than 1% incremental FX headwind relative to prior guidance. It narrowed non-GAAP EPS guidance to $7.25-7.35, absorbing a $290 million upfront payment to Orion and higher U.S. pension settlement expense against roughly $0.25 of operational strength. GAAP EPS guidance is $5.89-5.99. For investors, the key takeaways are the durability of KEYTRUDA and vaccine demand, the sizable but temporary contribution of LAGEVRIO, and a guidance range that absorbs FX and business development costs. The filing also contains forward-looking statements and risk factors, including competition, patent exposure, pricing pressure and regulatory outcomes.
Merck 8-K Report, Shareholder Vote Results (May 26, 2022)
Merck & Co., Inc. (MRK) filed an 8-K on May 25, 2022, detailing the outcomes of its Annual Meeting of Shareholders held on May 24, 2022. The report indicates that all director nominees were overwhelmingly elected, demonstrating strong shareholder confidence in the current board's leadership. Additionally, shareholders provided a non-binding advisory vote to approve executive compensation, which passed with a significant majority, and ratified the appointment of the company's independent registered public accounting firm for 2022, also with strong support. The filing also outlines the voting results on several shareholder proposals. Notably, proposals concerning an independent board chairman, access to COVID-19 products, and lobbying expenditure disclosure did not receive majority support, with a majority of votes cast being against each of these proposals. These results suggest that the company's current governance and policies, as perceived by the majority of its voting shareholders, align with their interests regarding these specific issues.
Merck 8-K Report, Financial Results (Apr 28, 2022)
Merck reported first-quarter 2022 results on a continuing operations basis (excluding Organon, spun off June 2, 2021) with worldwide sales of $15.9 billion, up 50% year over year (52% excluding foreign exchange). Growth was driven by the newly launched COVID-19 antiviral LAGEVRIO ($3.2 billion in sales, with no comparable sales in the prior-year quarter) and by strong performance from KEYTRUDA ($4.8 billion, up 23%) and GARDASIL/GARDASIL 9 ($1.5 billion, up 59%). Excluding LAGEVRIO, pharmaceutical sales grew 18%. GAAP EPS was $1.70 (up 57%), while non-GAAP EPS was $2.14 (up 84%). The GAAP-to-non-GAAP gap was largely driven by a $708 million net loss from equity-security investments, along with acquisition- and divestiture-related costs. Management raised and narrowed full-year 2022 guidance: sales of $56.9 to $58.1 billion (implying 17% to 19% growth), GAAP EPS of $5.90 to $6.02, and non-GAAP EPS of $7.24 to $7.36. The guidance includes $5.0 to $5.5 billion of expected LAGEVRIO sales and a roughly 2% negative FX impact. A methodology change also matters for comparability: beginning in 2022, Merck no longer excludes upfront and milestone payments for collaborations and licensing deals from non-GAAP results, aligning with SEC views. Prior-year non-GAAP results were recast, reducing 2021 non-GAAP EPS by $0.65 to $5.37. Investors should weigh the strong top-line momentum against several watch items: LAGEVRIO's contribution is significant but time-limited and carries lower margins due to profit sharing with Ridgeback, the company faces loss of exclusivity for JANUVIA and JANUMET in the EU and China in Q3 2022, and results depend on continued KEYTRUDA growth and the pipeline. Management also disclosed that the financial impact of the Russia-Ukraine conflict was immaterial to Q1 results.
Merck 8-K Report, Financial Results (Apr 21, 2022)
Merck & Co. (MRK) filed an 8-K on April 21, 2022 to disclose a change in how it calculates non-GAAP results, made to align with views expressed by SEC staff during a consultation with pharmaceutical peers. Beginning in 2022, Merck's non-GAAP results will no longer exclude expenses for upfront and milestone payments related to collaborations and licensing agreements, or charges for pre-approval assets acquired in asset acquisitions. Previously, these were excluded when considered significant to a given period. The change does not affect first quarter 2022 non-GAAP results or previously reported first quarter 2021 results, since no significant charges of this type occurred in those periods. It does affect previously reported non-GAAP results for other 2021 periods and for full year 2020. The recast figures in Exhibit 99.1 show the impact is material for certain periods. Full-year 2021 non-GAAP EPS from continuing operations is recast to $5.37 from $6.02 as previously reported, a reduction of $0.65 per share. Non-GAAP pretax income falls by about $1.66 billion, largely from R&D expenses that are now included rather than excluded, mainly related to the Pandion, VelosBio and OncoImmune acquisitions. Full-year 2020 non-GAAP EPS is recast to $2.97 from $4.53, a reduction of $1.56 per share, driven mainly by the $2.7 billion VelosBio charge, $1.1 billion in license and collaboration upfront payments, and $462 million OncoImmune charge now being included. The 2021 recast also reflects a tax rate change from 11.2% to 12.4%. For investors, this is primarily a presentation change rather than a change to GAAP results, cash flows or underlying operations. However, it makes non-GAAP earnings comparisons with prior periods less favorable for 2020 and 2021 and means that future non-GAAP results will be more conservative, since business development costs that were previously excluded now flow through earnings. Investors should compare recast figures when evaluating year-over-year trends.
Merck 8-K Report, Bylaw Amendment (Mar 25, 2022)
Merck & Co., Inc. (MRK) filed an 8-K on March 24, 2022, to report an amendment to its By-Laws, effective March 22, 2022. This amendment was made to align with recent changes in New Jersey law, specifically the New Jersey Business Corporation Act. The key change allows for shareholder meetings to be conducted via remote communication. This update is primarily a procedural change to ensure compliance with state law and does not appear to signal any significant shifts in the company's operational strategy or financial performance. Investors should note that this filing is administrative in nature, facilitating flexibility in how shareholder meetings are convened in the future, potentially increasing accessibility.
Merck 8-K Report, Financial Results (Feb 3, 2022)
Merck reported fourth-quarter and full-year 2021 results on February 3, 2022, on a continuing-operations basis (excluding Organon, spun off June 2, 2021). Fourth-quarter sales rose 24% to $13.5 billion (23% excluding FX), and full-year sales rose 17% to $48.7 billion (16% ex-FX). Growth was driven by KEYTRUDA (full-year $17.2 billion, up 20%), GARDASIL/GARDASIL 9 (up 44% to $5.7 billion), and the first $952 million of molnupiravir sales in the quarter. Fourth-quarter GAAP EPS was $1.51 and non-GAAP EPS was $1.80; full-year GAAP EPS was $4.86 and non-GAAP EPS was $6.02. Results were lifted by molnupiravir, a favorable full-year effective tax rate of 11.0%, and $1.3 billion of other income from equity-security gains, so the earnings quality is more mixed than the headline growth suggests. For 2022, Merck guided to revenue of $56.1 to $57.6 billion, GAAP EPS of $5.76 to $5.91, and non-GAAP EPS of $7.12 to $7.27. The revenue guide includes an estimated $5 to $6 billion from molnupiravir, so a meaningful share of expected growth depends on a COVID-19 treatment whose demand and pricing are uncertain. Non-GAAP gross margin is guided to about 74%, and non-GAAP operating expenses are expected to rise by a mid-to-high single-digit rate. Pipeline and regulatory news was mixed. The Acceleron acquisition closed, adding sotatercept for pulmonary arterial hypertension. Merck disclosed FDA clinical holds on several islatravir HIV programs after lymphocyte and CD4+ count declines, and it received a Complete Response Letter for gefapixant. Investors should watch the islatravir holds and the molnupiravir revenue assumptions most closely.
Merck 8-K Report, Corporate Update (Dec 10, 2021)
Merck & Co., Inc. (MRK) filed an 8-K on December 10, 2021, to report the closing of a significant public offering of senior notes. The company successfully raised a total of $8 billion across five different series of notes with varying maturity dates and coupon rates, ranging from 2027 to 2061. This debt issuance indicates Merck's strategic financial management, likely aimed at funding operations, potential acquisitions, research and development, or refinancing existing debt. The diverse range of maturities suggests a strategy to manage its debt profile effectively over the long term and capture favorable interest rates. Investors should note that while this filing doesn't directly impact current earnings, it provides insight into the company's capital structure and its proactive approach to managing its financial obligations and funding its growth initiatives.
Merck 8-K Report, Financial Results (Oct 28, 2021)
Merck reported third-quarter 2021 results on a continuing operations basis (excluding Organon, spun off June 2, 2021). Worldwide sales rose 20% to $13.2 billion (19% excluding foreign exchange), led by KEYTRUDA (up 22% to $4.5 billion) and GARDASIL/GARDASIL 9 (up 68% to $2.0 billion). GAAP EPS from continuing operations was $1.80 and non-GAAP EPS was $1.75, versus $0.92 and $1.37 a year earlier. The GAAP figure was lifted by roughly $684 million of income from equity securities investments, while the non-GAAP figure excludes that gain along with acquisition-related, restructuring and certain other items. Gross margin improved to 73.8% GAAP (76.8% non-GAAP). Management raised and narrowed full-year 2021 guidance. Revenue is now expected at $47.4 to $47.9 billion, implying 14% to 15% sales growth, including a roughly 1.5% foreign exchange benefit. GAAP EPS is guided to $4.71 to $4.76 and non-GAAP EPS to $5.65 to $5.70. Neither range includes potential launch revenue from molnupiravir, the oral COVID-19 antiviral for which Merck has filed an Emergency Use Authorization application with the FDA. Pipeline and regulatory news was also significant, including the pending $11.5 billion cash acquisition of Acceleron Pharma (sotatercept for pulmonary arterial hypertension), expected to close in Q4 2021, and several FDA and EMA approvals and priority reviews for KEYTRUDA and WELIREG. For investors, the quarter shows strong underlying demand, particularly in oncology and HPV vaccines. Key watch items include the FDA decision on molnupiravir (advisory committee meeting set for November 30, 2021), completion of the Acceleron deal, and the resumption of ZERBAXA supply after its 2020 recall. Pneumovax 23 sales declined 26%, and R&D spending remains elevated.
Merck 8-K Report, Executive Changes (Aug 20, 2021)
Merck & Co., Inc. (NYSE: MRK) filed this Form 8-K on August 20, 2021 to disclose that Leslie A. Brun, the company's independent lead director, resigned from its Board of Directors effective August 19, 2021. The filing is administrative in nature under Item 5.02 (Departure of Directors), with the substance provided in the attached press release (Exhibit 99.1). No financial results, guidance, or material operating developments are reported in this filing. Mr. Brun is stepping down to become chairman and chief executive officer of Ariel Alternatives, LLC, a subsidiary of Ariel Investments, LLC. This private equity initiative is being created to help scale minority-owned businesses into tier 1 suppliers for Fortune 500 companies. Merck stated it is currently evaluating making an investment in Ariel Alternatives, which is the one item that could have a direct, though likely modest, financial implication for the company if completed. Merck's CEO and President, Rob Davis, praised Mr. Brun's leadership and said the company wishes him success. The company intends to name a new independent lead director in the near future, so investors should watch for that announcement as the more meaningful governance development. The filing carries no indication of disagreement with management or the board, and the stated reason for departure is a new professional opportunity.
Merck 8-K Report, Financial Results (Jul 29, 2021)
Merck reported second-quarter 2021 results on a continuing operations basis, which now excludes Organon, the women's health, biosimilars and established brands business spun off on June 2, 2021. Worldwide sales rose 22% year over year to $11.4 billion (19% excluding foreign exchange), led by KEYTRUDA at $4.2 billion (+23%), GARDASIL/GARDASIL 9 at $1.2 billion (+88%) and Animal Health at $1.5 billion (+34%). The recovery from COVID-19 contributed an estimated $900 million to year-over-year growth, and the company said the pandemic's net unfavorable impact on 2021 revenue is now less than 3%. GAAP EPS fell 48% to $0.48, but this reflects a $1.7 billion charge for the acquisition of Pandion Therapeutics, which carries no tax benefit. Non-GAAP EPS rose 28% to $1.31. Gross margin declined on a non-GAAP basis to 76.5% from 77.1%, reflecting FX, pricing pressure and manufacturing costs, while R&D expense rose sharply on a GAAP basis, largely because of the Pandion charge. Management raised its full-year 2021 revenue guidance to $46.4 billion to $47.4 billion, with sales growth of 12% to 14%. It also raised non-GAAP EPS guidance to $5.47 to $5.57, while GAAP EPS guidance is $4.24 to $4.34. Beyond financials, the quarter included several regulatory approvals, including VAXNEUVANCE for adults and KEYTRUDA in early-stage triple-negative breast cancer. The company also withdrew a KEYTRUDA gastric cancer indication after an unfavorable advisory committee vote, and gefapixant's FDA review was extended to March 2022. Molnupiravir, the COVID-19 antiviral, is in Phase 3 and is not included in the guidance. Investors should weigh the strong underlying demand against the Pandion charge, the pricing pressure on JANUVIA and the regulatory risks noted above.
Merck 8-K Report, Regulation FD Disclosure (Jun 21, 2021)
On June 2, 2021, Merck completed the spinoff of its women's health, biosimilars and established brands businesses into a new, independent public company, Organon & Co., via a distribution of Organon stock to Merck shareholders. This 8-K recasts Merck's historical results to present those businesses as discontinued operations, so the figures now reflect a continuing-operations basis. Notably, the filing is primarily informational: it provides recast financials for Q1 2021, each quarter and full-year 2020, and full-year 2019, along with GAAP-to-non-GAAP reconciliations, but it does not provide new forward guidance. Merck says detailed guidance will come with its July 29, 2021 second-quarter earnings release. On a recast continuing-operations basis, Q1 2021 sales were $10.6 billion, excluding $1.5 billion of Organon product sales. Non-GAAP operating margin was 33.7%, down 1.8 points, because Organon products carried higher margins (about 45%) and Merck continues to absorb roughly $400 million of annual overhead previously allocated to Organon. Gross margin rose to 76.6% and the tax rate was 14.3% on a non-GAAP basis. Management had previously said 2021 operating margin would be slightly lower than pre-spinoff levels and that about $500 million of operating efficiencies were built into its February 2021 full-year outlook. For investors, the key takeaway is that Merck's post-spinoff earnings base is smaller in revenue but still highly profitable, with margin dilution expected to be modest and partly offset by cost actions. The 2020 figures include large non-GAAP-excluded charges, notably a $1.6 billion ZERBAXA impairment and $2.7 billion for the VelosBio acquisition, which affect GAAP comparisons. Investors should also note that cash flow and balance sheet impacts of the spinoff will not appear until the Q2 2021 Form 10-Q.
Merck 8-K Report, Acquisition Completed (Jun 3, 2021)
Merck & Co., Inc. (MRK) announced the completion of the separation of its Organon & Co. business segment, which housed its women's health, biosimilars, and established brands divisions. This separation occurred on June 2, 2021, following a distribution of Organon common stock to Merck shareholders of record as of May 17, 2021. Each Merck shareholder received one-tenth of a share of Organon for every share of Merck they held, with cash provided for fractional shares. The company structured this distribution to be tax-free for its shareholders, with the exception of cash received for fractional shares, making this a significant strategic move for Merck to focus on its core growth areas.
Merck 8-K Report, Shareholder Vote Results (May 27, 2021)
Merck & Co., Inc. (MRK) filed an 8-K on May 26, 2021, detailing the outcomes of its Annual Meeting of Shareholders held on May 25, 2021. The primary focus of the filing is the voting results on several key corporate governance matters. All director nominees were overwhelmingly elected, indicating strong shareholder confidence in the current board leadership. Similarly, shareholders approved the executive compensation package through a non-binding advisory vote and ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2021, underscoring shareholder trust in financial oversight and reporting. However, two shareholder proposals did not receive majority support. These included a proposal regarding shareholders' right to act by written consent and another concerning access to COVID-19 products. The outcomes of these votes suggest that the majority of shareholders did not favor these specific changes to corporate governance or operational directives at this time, reinforcing the board's current strategic direction and decision-making authority on these matters.
Merck 8-K Report, Temporary Suspension of Trading Under Employee Benefit Plans (May 5, 2021)
Merck & Co. (MRK) filed this Form 8-K on May 5, 2021 to disclose a temporary trading blackout affecting its employee benefit plans. The blackout relates to the planned separation of Organon & Co., Merck's former women's health and biosimilars business, which Merck intends to spin off to shareholders. Beginning at 4:00 p.m. Eastern Time on June 2, 2021, and continuing through the week of June 7, 2021, participants in the Merck U.S. Savings Plan, the MSD Employee Stock Purchase and Savings Plan, and the MSD Puerto Rico Savings & Security Plan will be unable to direct or diversify investments, take plan loans, or take distributions involving Merck common stock held in the Merck Common Stock Fund. The blackout is administrative in nature and is required so that Organon shares can be distributed as a dividend to Merck shareholders held within the 401(k) plans. The filing itself does not disclose financial results, guidance, or changes to Merck's operations. Its main significance for investors is procedural, but it signals that the Organon spin-off timeline was set for early June 2021. The notice also confirms that directors and executive officers are restricted from trading Merck shares and derivatives during the blackout period, as required under Sarbanes-Oxley Section 306 and Regulation BTR. Notably, the exhibit states that the start date could change if the spinoff date shifts, in which case Merck would provide updated notice. Investors seeking the actual dates can contact the Corporate Secretary, and the company must keep this information available for two years after the blackout ends.
Merck 8-K Report, Financial Results (Apr 29, 2021)
Merck & Co. (MRK) reported first-quarter 2021 sales of $12.1 billion, flat versus the prior year on a reported basis and down 1% excluding foreign exchange. The quarter was shaped by COVID-19 disruption to patient access, particularly for vaccines, which the company estimated reduced pharmaceutical revenue by roughly $600 million. Strength came from KEYTRUDA (up 19% to $3.9 billion), Lynparza alliance revenue (up 57%), BRIDION and Animal Health (up 17%). GAAP EPS was $1.25 versus $1.26 a year ago, and non-GAAP EPS was $1.40 versus $1.51, down 7%. GAAP results benefited from $561 million of equity-investment income and a $237 million one-time tax benefit, while non-GAAP results excluded acquisition costs, restructuring charges and a $188 million COVID-19 program discontinuation charge. Full-year 2021 guidance was maintained for sales of $51.8 to $53.8 billion (8% to 12% growth) and non-GAAP EPS of $6.48 to $6.68. GAAP EPS guidance was lowered to $5.05 to $5.25, primarily because of an expected $1.8 billion charge for the Pandion acquisition, which Merck completed on April 1, 2021. Management also noted that the pandemic is expected to reduce 2021 revenue by about 3%, and that guidance excludes any potential launch of its COVID-19 antiviral candidate, molnupiravir. The quarter's most significant strategic item is the planned spinoff of Organon, the women's health, biosimilars and established brands business. The spinoff is expected to close on June 2, 2021, with trading beginning June 3. Organon is expected to carry $9.5 billion of initial debt and to pay Merck a special dividend of about $9.0 billion, which Merck plans to use for business development or share repurchases. After the spinoff, Merck expects 2021 continuing-operations revenue of $45.8 to $47.8 billion, and it targets about $1.5 billion in operating efficiencies over three years.
Merck 8-K Report, Executive Changes (Mar 26, 2021)
Merck & Co., Inc. (MRK) filed an 8-K on March 25, 2021, detailing significant leadership changes. The report announced the upcoming retirement of CEO Kenneth C. Frazier, effective June 30, 2021, with Mr. Frazier transitioning to Executive Chairman. Robert M. Davis, currently EVP of Global Services and CFO, has been appointed President effective April 1, 2021, and is slated to become CEO and a Board member on July 1, 2021. This leadership transition is accompanied by updated compensation packages for both Mr. Frazier and Mr. Davis, reflecting their new roles and responsibilities. Additionally, Caroline Litchfield has been appointed as the new Executive Vice President and Chief Financial Officer, effective April 1, 2021. These executive changes and compensation adjustments are key points for investors to monitor as they signal a new phase of leadership and potential strategic direction for Merck.
Merck 8-K Report, Regulation FD Disclosure (Mar 24, 2021)
Merck & Co., Inc. filed an 8-K on March 24, 2021, primarily to disclose information regarding Organon & Co. The company made a presentation available on its website that included details about the planned spin-off of Organon, which is intended to be a new, publicly traded company comprising Merck's legacy brands, biosimilars, and women's health portfolio. This event is significant for Merck investors as it signals a strategic shift to focus on its innovative growth pillars, potentially unlocking value for shareholders by allowing Organon to operate independently with its distinct business strategy and capital allocation priorities.
Merck 8-K Report, Financial Results (Feb 4, 2021)
Merck reported fourth-quarter 2020 sales of $12.5 billion (up 5%) and full-year 2020 sales of $48.0 billion (up 2%, or 4% excluding foreign exchange). KEYTRUDA was the standout, with full-year sales up 30% to $14.4 billion. GAAP results were heavily affected by one-time charges: GAAP EPS was $(0.83) for the quarter and $2.78 for the year, versus non-GAAP EPS of $1.32 and $5.94. The largest charges were a $2.7 billion VelosBio acquisition charge, a $1.6 billion ZERBAXA intangible impairment following a recall, and $1.1 billion in collaboration-related charges. Pandemic impacts were negative on revenue (about $2.5 billion for the year) but partly offset by lower operating spending. The 2021 outlook calls for revenue of $51.8 to $53.8 billion, GAAP EPS of $5.52 to $5.72, and non-GAAP EPS of $6.48 to $6.68. Merck is also changing its non-GAAP methodology starting in 2021 to exclude all intangible amortization and equity-security gains and losses. On that new basis, 2020 non-GAAP EPS would have been $5.79, so investors should compare guidance against the recast figure rather than the originally reported $5.94. The most significant strategic item is the planned spinoff of Organon & Co., expected in late Q2 2021. Organon's 2020 revenue was $6.5 billion, and Merck expects a special dividend to itself of roughly $8.5 to $9.0 billion plus $9.0 to $9.5 billion in initial debt at Organon. Merck expects about $1.5 billion in efficiencies over three years and anticipates higher combined non-GAAP EPS within 12 to 24 months after the spin. The guidance excludes any potential launch of its COVID-19 antiviral candidates, and the KEYNOTE-122 nasopharyngeal trial missed its overall survival endpoint.
Merck 8-K Report, Executive Changes (Feb 4, 2021)
Merck & Co. (MRK) announced on February 4, 2021 a planned CEO succession. Chairman and CEO Kenneth C. Frazier will retire as Chief Executive Officer effective June 30, 2021, and will remain as Executive Chairman for a transition period to be set by the Board. The Board unanimously elected Robert M. Davis, currently Executive Vice President, Global Services and Chief Financial Officer, to serve as President effective April 1, 2021, and as CEO and a director effective July 1, 2021. The filing contains no financial results, guidance, or material financial data; its investor relevance lies in governance and leadership continuity. Davis's elevation is a significant change for investors because he has been deeply involved in Merck's strategy and finance functions. He joined Merck as CFO in 2014 and in 2016 took on oversight of global support functions including corporate business development, investor relations, IT, procurement, real estate, and corporate strategy. Before Merck, he held senior roles at Baxter, including president of Medical Products, and spent more than 14 years at Eli Lilly. From April 1, 2021, the operating divisions (Human Health, Animal Health, Manufacturing, and Merck Research Laboratories) will report to him, giving him operational authority ahead of his formal CEO start date. The Board framed the transition as continuity rather than a change in direction. Frazier described Davis as a strategic partner with deep industry knowledge, and Lead Independent Director Les Brun pointed to Davis's work alongside Dean Li, president of Merck Research Laboratories, to sustain scientific excellence. Davis said he intends to continue Frazier's focus on innovation and aspires to make Merck the premier research-intensive biopharmaceutical company. The company also flagged the COVID-19 pandemic as a source of uncertainty in the year ahead.
Merck 8-K Report, Executive Changes (Feb 1, 2021)
Merck & Co. (MRK) filed a Form 8-K on February 1, 2021 under Item 5.02 to announce that Dr. Stephen L. Mayo, Bren Professor of Biology and Chemistry at the California Institute of Technology, will join the Board of Directors effective March 15, 2021. Upon joining, the Board will have 14 members. Dr. Mayo was appointed to both the Research Committee and the Audit Committee, which is a notable assignment given his scientific background in protein design and the Audit Committee's oversight role. For investors, this is a routine governance event rather than a material financial disclosure. The filing contains no financial results, guidance, or changes to Merck's capital structure, and Dr. Mayo's compensation will follow the company's standard non-employee director program as described in the April 6, 2020 proxy statement. The filing also states that Dr. Mayo has no undisclosed related-party transactions under Item 404(a) of Regulation S-K and no arrangements with other persons tied to his election. The appointment strengthens Merck's scientific oversight at the board level, particularly through the Research Committee, as the company manages pipeline development and competition in the biopharmaceutical sector. Dr. Mayo will stand for shareholder election at the Annual Meeting on May 25, 2021. The release also lists forward-looking risk factors, including COVID-19, drug pricing and health care legislation, patent exposure, and new product development challenges.